Clonidine Versus Adenosine to Treat Neuropathic Pain
CompletedPhase 2NCT00349921
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
Study details
- Official title
- Clonidine Versus Adenosine to Treat Neuropathic Pain
- Conditions
- Interventions
- Drug: clonidine
- Drug: adenosine
- Drug: placebo
- Drug: placebo
- Sponsor
- Wake Forest University Health Sciences
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- Start date
- 2004-08
- Primary completion
- 2008-01
- Sex
- All
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients with complex regional pain syndrome (CRPS), type I involving a lower extremity Exclusion Criteria: * Pregnancy * Allergy to clonidine * Currently taking clonidine or other direct a2-adrenergic agonists, or taking cholinesterase inhibitors * Patients with any serious or unstable medical problems (heart, lung, liver, kidney, or nervous system disease)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00349921